India's Contract Development and Manufacturing Organization (CDMO) market is poised for exponential growth, expected to expand from USD 7 billion to USD 14 billion by 2028, capturing 4-5 per cent of the global market, according to BCG report.
This surge is driven by India's strong position in Active Pharmaceutical ingredients (API) and generic drug manufacturing, along with cost advantages over China.
Some Indian CDMOs have witnessed a 50 per cent year-on-year increase in Requests for Proposals (RFPs) in 2024, as global pharmaceutical companies look to diversify supply chains beyond China. Indian pharma services are priced 20 per cent lower than their Chinese counterparts, making them a competitive alternative.
With the global CDMO market for new drug modalities expected to reach USD 20 billion by 2028, Asian CDMOs are emerging as key players, offering scalable, cost-effective solutions for global pharmaceutical companies.
Source: msn
#medtechinindia #medtechstartup #dseidehealthcarenetwork
This surge is driven by India's strong position in Active Pharmaceutical ingredients (API) and generic drug manufacturing, along with cost advantages over China.
Some Indian CDMOs have witnessed a 50 per cent year-on-year increase in Requests for Proposals (RFPs) in 2024, as global pharmaceutical companies look to diversify supply chains beyond China. Indian pharma services are priced 20 per cent lower than their Chinese counterparts, making them a competitive alternative.
With the global CDMO market for new drug modalities expected to reach USD 20 billion by 2028, Asian CDMOs are emerging as key players, offering scalable, cost-effective solutions for global pharmaceutical companies.
Source: msn
#medtechinindia #medtechstartup #dseidehealthcarenetwork
India's Contract Development and Manufacturing Organization (CDMO) market is poised for exponential growth, expected to expand from USD 7 billion to USD 14 billion by 2028, capturing 4-5 per cent of the global market, according to BCG report.
This surge is driven by India's strong position in Active Pharmaceutical ingredients (API) and generic drug manufacturing, along with cost advantages over China.
Some Indian CDMOs have witnessed a 50 per cent year-on-year increase in Requests for Proposals (RFPs) in 2024, as global pharmaceutical companies look to diversify supply chains beyond China. Indian pharma services are priced 20 per cent lower than their Chinese counterparts, making them a competitive alternative.
With the global CDMO market for new drug modalities expected to reach USD 20 billion by 2028, Asian CDMOs are emerging as key players, offering scalable, cost-effective solutions for global pharmaceutical companies.
Source: msn
#medtechinindia #medtechstartup #dseidehealthcarenetwork
